Symptom-based phenotyping remains essential for clinical documentation and understanding patient experience, but it does not necessarily explain underlying pathophysiology. Fatigue, cognitive complaints, orthostatic tachycardia, dizziness, post-exertional symptoms, and gastrointestinal issues are clinical manifestations. Similar symptom patterns can plausibly arise from different biological processes. ^[1,4,7]

That heterogeneity creates a research challenge when participants are grouped solely by shared clinical features. Two people with severe fatigue, for example, might have different dominant physiological abnormalities—such as autonomic or hemodynamic dysfunction, metabolic abnormalities, or immune-related changes. These possibilities remain areas of active investigation rather than clinically validated endotypes. ^[1,4]

The field is evaluating measurable parameters that include autonomic function, endothelial and microcirculatory markers, immune profiling, metabolic indicators, mitochondrial measures, and gut-related biomarkers. Many proposed biomarkers remain experimental or investigational, and routine clinical testing cannot currently define every proposed mechanism. ^[1,4]

In research, mechanism-based evaluation aims to determine which physiological domains are disrupted in a given subgroup. In clinical trials, validated biological endotypes could reduce cohort heterogeneity and make it easier to determine whether an intervention affects the pathway it was designed to target. ^[1]

Post-viral syndromes can cross traditional organ-system boundaries. Patients may report combinations of autonomic, vascular, gastrointestinal, cognitive, and metabolic symptoms, and current research is examining whether some of these abnormalities interact rather than occur independently. ^[4,7]

Current literature is investigating several potentially interacting pathways:

• Autonomic dysregulation: Altered autonomic control can affect heart rate, blood pressure regulation, gastrointestinal motility, and other dynamic physiological responses. ^[5]

• Vascular and endothelial factors: Studies are examining endothelial activation and microcirculatory abnormalities as possible contributors to Long COVID pathophysiology. ^[4]

• Mast-cell and immune pathways: Mast-cell mediators and other immune signals are being studied for possible effects on vascular tone, permeability, and inflammatory signaling; their role likely varies across patients and remains incompletely defined. ^[4]

• Metabolic and gut-related pathways: Metabolic abnormalities, microbiome changes, and gut-barrier dysfunction are among several mechanisms under active investigation. ^[4,7]

Network models hypothesize that these systems may influence one another through bidirectional feedback. For example, autonomic changes can affect peripheral perfusion, while vascular or inflammatory signaling could in turn influence autonomic regulation. These interactions remain working hypotheses, and further research is needed to determine which relationships are reproducible, causal, and clinically important. ^[1]

Fragile mitophagy is a theoretical framework proposed to describe a possible vulnerability in cellular quality control after metabolic stress. [2]

Mitophagy is the process by which cells identify and remove damaged mitochondria through autophagic and lysosomal pathways, followed by repair and mitochondrial renewal. The fragile mitophagy hypothesis proposes that, in a subset of patients, mitochondrial injury and mitophagy may be initiated but lysosomal completion of that process may be insufficient when physiological demand increases. ^[2]

If that hypothesis is correct, incompletely cleared mitochondrial material could contribute to oxidative and inflammatory signaling and prolong recovery after exertion. The model was proposed as one possible explanation for delayed PEM, which can emerge hours after activity rather than exclusively during exertion. ^[2,3,6]

This remains an exploratory hypothesis. Patient studies have reported metabolic, mitochondrial, and muscle abnormalities in Long COVID, including changes associated with PEM, but they do not yet establish defective dynamic mitophagy flux or impaired lysosomal completion as the cause of PEM. ^[2,6]

 Deconditioning can contribute to exercise intolerance, but it does not fully account for the characteristic delayed symptom exacerbation described as post-exertional malaise. PEM is recognized in ME/CFS diagnostic frameworks and has also been documented in Long COVID research. ^[3,6]

A recovery-failure hypothesis suggests that at least some PEM may involve abnormal cellular recovery after exertion rather than only reduced conditioning or immediate energy depletion. In the fragile mitophagy model, metabolic demand could expose a weakness in mitochondrial clearance and recovery processes. ^[2]

That proposed mechanism has not been clinically validated. Researchers still need reproducible biomarkers that can distinguish specific cellular recovery abnormalities from other contributors to exercise intolerance and post-exertional symptoms. ^[2,6]

Routine blood tests can help identify alternative or contributing conditions such as anemia, electrolyte or metabolic abnormalities, thyroid disease, and—in the appropriate clinical context—evidence of infection or inflammation. They do not, however, directly measure the dynamic autonomic response to standing.

POTS is defined by an excessive sustained heart-rate increase with upright posture in the absence of orthostatic hypotension, together with an appropriate clinical history. The syndrome is heterogeneous, and published literature describes potential contributors that include neuropathic mechanisms, hyperadrenergic physiology, and hypovolemia. ^[5]

When clinically indicated, evaluation may incorporate orthostatic vital signs or an active standing test, formal tilt-table testing, and selected autonomic testing rather than relying only on resting laboratory values. ^[5] The appropriate workup depends on the individual presentation and should follow established clinical guidance rather than any single proposed mechanism.

One major challenge in post-viral research is biological heterogeneity. If an intervention is designed to act on a specific pathway, testing it across an unselected population may make a subgroup-specific effect more difficult to detect. ^[1,4,7]

For example, if a targeted biological abnormality were present in only 20% of an unselected trial population, a meaningful response confined to that subgroup could be diluted in the aggregate analysis. That 20% figure is hypothetical; it illustrates a trial-design problem rather than an estimate of the prevalence of any particular endotype.

Biomarker-driven or physiological stratification could allow researchers to enrich study cohorts for participants whose measured biology matches an intervention's proposed mechanism. This could also make neutral trials more informative by helping distinguish a genuinely ineffective intervention from one tested in a population that did not contain enough participants with the targeted abnormality. The key requirement is that the proposed biomarker or endotype first be independently validated. ^[1]